Neuroprotection for Parkinson's disease: a call for clinically driven experimental design

被引：14

作者：

Bezard, E ^{[1
]}

机构：

[1] Univ Victor Segalen, CNRS, UMR 5543, Neurophysiol Lab, F-33076 Bordeaux, France

来源：

LANCET NEUROLOGY | 2003年 / 2卷 / 07期

关键词：

D O I：

10.1016/S1474-4422(03)00432-0

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：393 / 393

页数：1

共 6 条

[1] Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease [J].

Bezard, E ;

Dovero, S ;

Prunier, C ;

Ravenscroft, P ;

Chalon, S ;

Guilloteau, D ;

Crossman, AR ;

Bioulac, B ;

Brotchie, JM ;

Gross, CE .

JOURNAL OF NEUROSCIENCE, 2001, 21 (17) :6853-6861

[2] Neuroprotective and neurorestorative strategies for Parkinson's disease [J].

Dawson, TM ;

Dawson, VL .

NATURE NEUROSCIENCE, 2002, 5 (Suppl 11) :1058-1061

[3] EQUIPOISE AND THE ETHICS OF CLINICAL RESEARCH [J].

FREEDMAN, B .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (03) :141-145

[4] Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: A novel therapy for Parkinson's disease [J].

Kaur, D ;

Yantiri, F ;

Rajagopalan, S ;

Kumar, J ;

Mo, JO ;

Boonplueang, R ;

Viswanath, V ;

Jacobs, R ;

Yang, L ;

Beal, MF ;

DiMonte, D ;

Volitaskis, I ;

Ellerby, L ;

Cherny, RA ;

Bush, AI ;

Andersen, JK .

NEURON, 2003, 37 (06) :899-909

[5] Neuroprotective agents for clinical trials in Parkinson's disease - A systematic assessment [J].

Ravina, BM ;

Fagan, SC ;

Hart, RG ;

Hovinga, CA ;

Murphy, DD ;

Dawson, TM ;

Marler, JR .

NEUROLOGY, 2003, 60 (08) :1234-1240

[6]

2003, LANCET NEUROLOGY, V2, P267

← 1 →